Royalty Pharma plc (RPRX)

Royalty Pharma Stock Forecast

Stock Price Forecast

According to 3 professional analysts, the 12-month price target for Royalty Pharma stock ranges from a low of $42 to a high of $54. The average analyst price target of $46 forecasts a 15.78% increase in the stock price over the next year.

Price Target: $46.00 (+15.78%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$42	$46	$42	$54
Change	+5.71%	+15.78%	+5.71%	+35.92%

* Price targets were last updated on Oct 10, 2025.

Analyst Ratings

The average analyst rating for Royalty Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	3	3	3	3	3	2
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Maintains $55 → $54	Buy	Maintains	$55 → $54	+35.92%	Oct 10, 2025
Asad Haider Goldman Sachs	Goldman Sachs	Strong Buy Initiates $42	Strong Buy	Initiates	$42	+5.71%	Sep 30, 2025
Geoff Meacham Citigroup	Citigroup	Strong Buy Maintains $40 → $42	Strong Buy	Maintains	$40 → $42	+5.71%	Jul 22, 2025
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Maintains $51 → $54	Buy	Maintains	$51 → $54	+35.92%	Jul 10, 2025
Andrew Baum Citigroup	Citigroup	Strong Buy Maintains $60 → $40	Strong Buy	Maintains	$60 → $40	+0.68%	Oct 25, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

3.10B

Increased by 37.13%

from 2.26B

Revenue Next Year

3.15B

Increased by 1.48%

from 3.10B

EPS This Year

4.81

Increased by 151.65%

from 1.91

EPS Next Year

5.19

Increased by 7.79%

from 4.81

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.12B	2.29B	2.24B	2.35B	2.26B	3.10B	3.15B
Revenue Growth	16.98%	7.87%	-2.28%	5.24%	-3.86%	37.13%	1.48%
EPS	1.32	1.49	0.10	2.53	1.91	4.81	5.19
EPS Growth	-	12.97%	-93.44%	2,490.74%	-24.54%	151.65%	7.79%
Forward PE	-	-	-	-	-	8.26	7.66
No. Analysts	-	-	-	-	-	12	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	3.4B	3.6B
Avg	3.1B	3.2B
Low	2.4B	2.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	50.2%	15.5%
Avg	37.1%	1.5%
Low	4.8%	-17.8%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	5.01	5.72
Avg	4.81	5.19
Low	4.57	4.44

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	162.0%	18.9%
Avg	151.7%	7.8%
Low	138.9%	-7.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.